Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Beltran NM, Ramos J, Landavazo A, Blough BE, Serafine KM. Eating a high fat diet enhances sensitivity of rats to serotonin receptor agonists. Physiol Behav. 2025 Oct 15; 300:115031.
-
Ramos-Benitez MJ, Miao R, Rivera-Torres AP, Lacourt-Ventura M, Malavez-Cajigas SJ, Tian X, Teague HL, De Jesus-Rojas W, Reger R, Suffredini AF, King C, Nathan SD, Childs RW, Strich JR. Surfactant Protein D and Club Cell Secretory Protein as Biomarkers of Disease Severity and Fostamatinib Efficacy in Severe COVID-19. Crit Care Explor. 2025 Apr 01; 7(4):e1252.
-
Schultheiss A, White J, Le K, Boone N, Riaz U, Taylor DK. The Synthesis, Characterization, and Theoretical Study of Ruthenium (II) Polypyridyl Oligomer Hybrid Structures with Reduced Graphene Oxide for Enhanced Optoelectronic Applications. Int J Mol Sci. 2024 Dec 03; 25(23).
-
Bhalodiya SS, Parmar MP, Patel CD, Patel SG, Vala DP, Suresh N, Jayachandran B, Kumar Arumugam M, Narayan M, Patel HM. Acetic Acid-Driven One-Pot Synthesis of 4,7-dihydro-[1,2,3]thiadiazolo[5,4-b]pyridine-6-carboxamides and Pharmacological Evaluations. ChemMedChem. 2025 Jan 14; 20(2):e202400595.
-
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
El-Bayaa MN, Kotb ER, Messaoudi S, Awad HM, Saleh MG, Soliman HA. Synthesis, anticancer activity, docking and computational studies of new pyridyl-glycosyl hybrids and acyclic analogs. Future Med Chem. 2024; 16(20):2119-2133.
-
Dash S, Hanson S, King B, Nyswaner K, Foss K, Tesi N, Harvey MJB, Navarro-Marchal SA, Woods A, Poradosu E, Unciti-Broceta A, Carragher NO, Brognard J. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas. J Biol Chem. 2024 09; 300(9):107615.
-
Warner S, Teague HL, Ramos-Benitez MJ, Panicker S, Allen K, Gairhe S, Moyer T, Parachalil Gopalan B, Douagi I, Shet A, Kanthi Y, Suffredini AF, Chertow DS, Strich JR. R406 reduces lipopolysaccharide-induced neutrophil activation. Cell Immunol. 2024 Sep-Oct; 403-404:104860.
-
Abu Rabe D, Chdid L, Lamson DR, Laudeman CP, Tarpley M, Elsayed N, Smith GR, Zheng W, Dixon MS, Williams KP. Identification of Novel GANT61 Analogs with Activity in Hedgehog Functional Assays and GLI1-Dependent Cancer Cells. Molecules. 2024 Jun 28; 29(13).
-
Xu X, Herdendorf TJ, Duan H, Rohlik DL, Roy S, Zhou H, Alkhateeb H, Khandelwal S, Zhou Q, Li P, Arepally GM, Walker JK, Garcia BL, Geisbrecht BV. Inhibition of the C1s Protease and the Classical Complement Pathway by 6-(4-Phenylpiperazin-1-yl)Pyridine-3-Carboximidamide and Chemical Analogs. J Immunol. 2024 02 15; 212(4):689-701.